What is Tesamorelin?
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue modified by the addition of a trans-3-hexenoic acid moiety to the C-terminus of GHRH 1-44. This structural modification extends its half-life to approximately 26 minutes, significantly longer than unmodified GHRH or sermorelin. FDA-approved in 2010 under the brand name Egrifta, tesamorelin is indicated for the treatment of HIV-associated lipodystrophy (abnormal fat distribution) and has become the gold standard for selectively reducing visceral adipose tissue in both HIV-positive and HIV-negative populations.
Mechanism of Action
Tesamorelin binds to the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating the synthesis and secretion of endogenous growth hormone. The trans-3-hexenoic acid modification protects the peptide from rapid enzymatic degradation, allowing sustained GHRH signaling over its 26-minute half-life. The elevated endogenous GH then acts on GH receptors throughout the body, particularly on adipocytes in the visceral fat depot, promoting lipolysis and reducing central fat accumulation. Tesamorelin preserves the physiological pulsatile pattern of GH secretion, maintaining normal feedback regulation unlike exogenous rhGH replacement.
Research & Studies
Tesamorelin's efficacy was rigorously demonstrated in landmark clinical trials. A pivotal double-blind, placebo-controlled study by Falutz et al., published in The New England Journal of Medicine (2010), enrolled 412 HIV-positive patients with lipodystrophy. Over 52 weeks of treatment with tesamorelin 2 mg daily, patients experienced a mean 20% reduction in visceral adipose tissue and improvements in cardiometabolic markers, while subcutaneous fat remained relatively preserved. This selectivity for visceral over subcutaneous fat is a key advantage of tesamorelin.
A follow-up open-label extension by Falutz et al. (2010) demonstrated sustained efficacy and safety over 104 weeks of continuous use. More recent studies have expanded tesamorelin's use beyond HIV populations. Stanley et al. (2014) in Diabetes Care showed that tesamorelin reduces visceral fat and improves insulin sensitivity in non-HIV obese men, with effects comparable to the HIV population.
Common Uses
- HIV-associated lipodystrophy: FDA-approved primary indication; reduces central fat redistribution
- Visceral fat reduction: Off-label use in metabolic syndrome and insulin resistance for preferential visceral fat loss
- Cardiometabolic optimization: Improves dyslipidemia, HOMA-IR, and cardiovascular risk markers
- Body recomposition: Selectively depletes visceral fat while preserving or enhancing lean mass
- Age-related central obesity: Used off-label in aging men to combat age-related visceral fat gain
Dosing & Protocol
Standard dosing: Tesamorelin 2 mg (2000 mcg) administered via subcutaneous injection once daily, typically in the evening. Clinical trials and FDA approval were based on this 2 mg daily regimen.
Alternative dosing: Some protocols use 1.4 mg daily (lower dose with similar visceral fat reduction but potentially fewer side effects) or 2 mg 5–6 days per week on a cycling protocol to reduce tachyphylaxis.
Timing: Evening injection before bed optimizes alignment with endogenous GH pulsatility and may enhance sleep-mediated GH surge.
Half-life: ~26 minutes, allowing for once-daily dosing with meaningful GH elevation throughout the day and night.
Cycle length: Tesamorelin efficacy requires 12+ weeks to observe significant visceral fat reduction; most clinical protocols recommend 12–24 weeks per cycle. Continuous use for 52+ weeks shows sustained and progressive benefit.
Synergies
Tesamorelin synergizes powerfully with GHRP-2 or Ipamorelin (ghrelin mimetics), creating a complementary GH axis stimulation that produces greater visceral fat reduction than tesamorelin alone. The GHRH + GHRP stack enhances GH pulse amplitude and frequency, accelerating visceral lipolysis.
Tesamorelin also pairs well with Semaglutide or Tirzepatide (GLP-1/GIP agonists) for synergistic metabolic improvement; the combination provides both GH-mediated visceral fat reduction and GLP-1-mediated appetite suppression and insulin sensitization. AOD-9604 (lipotropic peptide) is another excellent partner, targeting adipose tissue remodeling from complementary pathways.
Receptor Overlaps & Avoidance
Critical: Do NOT combine tesamorelin with other GHRH analogues such as sermorelin or CJC-1295. All bind the same GHRHR receptor; stacking causes receptor saturation with no synergistic GH benefit and increased risk of side effects (hypertension, carpal tunnel, joint pain from excessive GH signaling).
Do not stack GHRP-2 with GHRP-6 simultaneously—receptor competition reduces overall efficacy. Choose one GHRP to pair with tesamorelin.
Tesamorelin is fully compatible with non-axis peptides (BPC-157, TB-500, GHK-Cu) and metabolic peptides (semaglutide, tirzepatide) that act through distinct mechanisms.
Safety Profile
Tesamorelin has a well-established safety profile from extensive clinical trials in both HIV and non-HIV populations:
- Injection site reactions: Mild erythema or induration (10–20% of users)
- Carpal tunnel syndrome: Reported in 1–2% of users; reversible upon discontinuation
- Joint/muscle pain: Transient arthralgias in 5–10%; typically mild and self-resolving
- Hyperglycemia: Minimal impact on fasting glucose; some users with diabetes may require slight medication adjustment
- Edema: Rare; minimal weight gain despite GH elevation (fat loss offsets lean mass gain)
- No cortisol or prolactin elevation: Unlike GHRP-2, tesamorelin does not meaningfully elevate these hormones
Long-term safety data extends to 104+ weeks with no loss of efficacy, antibody formation, or cumulative adverse effects. Tesamorelin is contraindicated in active malignancy due to theoretical GH-mediated tumor promotion, though no cases have been documented in clinical populations.